Tofogliflozin (hydrate)

CAS : 1201913-82-7

Ref. 3D-BYB91382

Informations sur le produit

• Nom: Tofogliflozin (hydrate)
• Synonymes: Tofogliflozin hydrate, Deberza, Spiro[isobenzofuran-1(3H),2′-[2H]pyran]-3′,4′,5′-triol, 6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydro-6′-(hydroxymethyl)-, hydrate (1:1), (1S,3′R,4′S,5′S,6′R)-

Description

Tofogliflozin is a novel oral anti-diabetic drug that belongs to the class of glp-1r agonists. It is used in combination therapy with metformin or sulfonylureas for type 2 diabetes mellitus. Tofogliflozin inhibits the renal glucose transport and, as a consequence, slows renal glucose reabsorption and lowers blood sugar levels. In addition, it has been shown to reduce blood pressure by blocking the angiotensin II receptor AT1 in the vascular walls of the kidneys. Tofogliflozin has also been shown to improve disease activity, hepatic steatosis, and hepatic impairment in patients with inflammatory bowel disease and nonalcoholic steatohepatitis (NASH). Tofogliflozin is an inhibitor of dapagliflozin, which blocks the action of sodium-glucose cotransporter 2 (SGLT2).

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 404.45 g/mol
• Formule: C₂₂H₂₈O₇
• Degré de pureté: Min. 95%